Selective role of glutathione in protecting human neuronal cells from dopamine-induced apoptosis

Neuropharmacology

Volumn 35, Issue 5, 1996, Pages 571-578

  Gabbay, M ^a   Tauber, M ^a   Porat, S ^a   Simantov, R ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Antioxidant; Apoptosis; Dopamine; Glutathione; Neurodegeneration; Neurotoxicity; Parkinson's disease; Programmed cell death

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BUTHIONINE SULFOXIMINE; CYSTEINE; DNA FRAGMENT; DOPAMINE; GAMMA GLUTAMYLCYSTEINE SYNTHETASE INHIBITOR; GLUTATHIONE; LACTATE DEHYDROGENASE; UNCLASSIFIED DRUG;

AGING; APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROTECTION; CELL STRUCTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG SELECTIVITY; ENZYME RELEASE; HUMAN; HUMAN CELL; NERVE CELL CULTURE; NERVE DEGENERATION; NEUROBLASTOMA CELL; NEUROTOXICITY; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0030152005     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/0028-3908(96)84626-0     Document Type: Article

References (53)

1. Bai C., Brown L.A., Jones D.P. Glutathione transport by type H cells in perfused rat lung. Am. J. Physiol. 267:1994;L447-L455.
2. Bannon M.J., Poosch M.S., Xia Y., Goebel D.J., Cassin B., Kapatos G. Dopamine transporter mRNA content in human substantia nigra decreases precipittously with age. Proc. natn. Acad. Sci. U.S.A. 89:1992;7095-7099.
3. Bergelson S., Pinkus R., Daniel V. Induction of AP-1 (Fos/Jun) by chemical agents mediates activation of glutathione S-transferase and quinone reductase gene expression. Oncogene. 9:1994;565-571.
4. Bindoff L.A., Birch-Machin M., Cartlidge N.E.F., Parker W.D. Jr., Turnbull D.M. Mitochondrial function in Parkinson's disease. Lancet. 2:1989;49.
5. Brodeur G.M., Sekhon G.S., Goldstein M.N. Chromosomal aberrations in human neuroblastomas. Cancer. 40:1977;2256-2263.
6. Burns R.S., Chiueh C.C., Markey S.P., Herbert M.H., Jacobowitz D.M., Kopin I.J. A primate model of Parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the sustantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. natn. Acad. Sci. U.S.A. 80:1983;4546-4550.
7. Boyne A.F., Ellman G.A. A methodology for analysis of tissue sulfhydryl compounds. Analyt. Biochem. 46:1992;639-653.
8. Calne D.B., Langston J.W. Aetiology of Parkinson's disease. Lancet. 2:1983;1457-1459.
9. Carlsson A., Winblad B. Influence of age and time interval between death and autopsy on dopamine and 3-methoxytyramine levels in human basal ganglia. J. neural Transm. 38:1976;271-276.
10. Cleeter M.W., Cooper J.M., Schapira A.H. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J. Neurochem. 58:1992;786-789.
11. Coyle J.T., Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 262:1993;689-695.
12. Damier P., Hirsch E.C., Zhang P., Agid Y., Jvoy-Agid F. Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience. 52:1993;1-6.
13. De Erausquin G.A., Costa E., Hanbauer I. Calcium homeostasis, free radical formation and trophic factor dependence mechanisms in Parkinson's disease. Pharmacol. Rev. 46:1994;467-482.
14. De Keyser J., Ebinger G., Vauquelin G. Age-related changes in the human nigrostriatal dopaminergic system. Ann. Neurol. 27:1990;157-161.
15. Di Monte D., Smith M.T. Free radicals, lipid oxidation and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Rev. Neurosci. 2:1988;67-81.
16. Dipasquale B., Marini A.M., Youle R.J. Apoptosis and DNA degradation induced by 1-methyl-4-phenylpyridinium in neurons. Biochem. biophys. Res. Commun. 181:1991;1442-1448.
17. Fahn S., Cohen G. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it. Ann. Neurol. 32:1992;804-812.
18. Fernandes R.S., Cotter T.G. Apoptosis or necrosis: intracellular levels of glutathione influence mode of cell death. Biochem. Pharmacol. 48:1994;675-681.
19. Fornstedt B., Pilblad E., Carlsson A. In vivo auto-oxidation of dopamine in guinea pig striatum increases with age. J. Neurochem. 55:1990;35-42.
20. Gerlach M., Riederer P., Przuntek H., Youdin M.B.H. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur. J. Pharmacol. 208:1991;273-276.
21. Heikkila R.E., Hess A., Duvoisin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Science. 224:1984;1451-1453.
22. Hornykiewicz O. Parkinson's disease: from brain homogenate to treatment. Fed. Proc. 32:1973;183-190.
23. Jenner P., Dexter D.T., Sian J., Schapira A.H.V., Marsden C.D. Oxidative stress as cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. Ann. Neurol. 32:1992;S82-S87.
24. Johannsen P., Velander G., Mai J., Thorling E.B., Dupont E. Glutathione peroxidase in early and advanced Parkinson's disease. J. Neurol. Neurosurg. Psychiat. 54:1991;679-682.
25. Kish S.J., Morito C.L.H., Hornykiewicz O. Brain glutathione peroxidase in neurodegenerative disorders. Neurochem. Pathol. 4:1986;23-28.
26. Kopin I.J. Parkinson's disease: past, present and future. Neuropsychopharmacology. 9:1992;1-12.
27. Korsmeyer S.J., Shutter J.R., Veis D.J., Merry D.E., Oltvai Z.N. Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin. Cancer Biol. 4:1993;327-332.
28. Kurita T., Namiki H. Apoptotic cell death induced by serum and its prevention by thiols. J. Cell Physiol. 161:1994;63-70.
29. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980.
30. Levy E.J., Anderson M.E., Meister A. Transport of glutathione diethyl ester into human cells. Proc. natn. Acad. Sci. U.S.A. 90:1993;9171-9175.
31. Malorni W., Rivabene R., Santini M.T., Donelli G. N-Acetylcysteine inhibits apoptosis and decreases viral particles in HIV-chronically infected U937 cells. FEBS Lett. 327:1993;75-78.
32. Meister A. Glutathione, ascorbate, and cellular protection. Cancer Res. 54:1994;s1969-s1975.
33. Mizurio Y., Ohta S., Tanaka M., Takamiya S., Suzuki K., Sato T., Oya H., Ozawa T., Kagawa Y. Deficiencies in Complex I subunits of the respiratory chain in Parkinson's disease. Biochem. biophys. Res. Commun. 163:1989;1450-1455.
34. Mytilineou C., Han S.K., Cohen G. Toxic and protective effects of L-dopa on mesencephalic cell cultures. J. Neurochem. 61:1993;1470-1478.
35. Olanow C.W. A radical hypothesis for neurodegeneration. Trends Neurosci. 16:1993;439-444.
36. Parker W.D., Boyson S.J., Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26:1989;719-723.
37. Perry T.L., Godin D.V., Hansen S. Parkinson's disease: A disorder due to nigral glutathione deficiency. Neurosci. Lett. 33:1982;305-310.
38. Ratan R.R., Murphy T.H., Baraban J.M. Macromolecular synthesis inhibitors prevent oxidative stress-induced apoptosis in embryonic cortical neurons by shunting cysteine from protein synthesis to glutathione. J. Neurosci. 14:1994;4385-4392.
39. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., Youdim M.B.H. Transition metals, ferritin, glutathione and ascorbic acid in Parkinsonian brains. J. Neurochem. 52:1989;515-520.
40. Sampath D., Jackson G.R., Werrbach-Perez K., Perez-Polo J.R. Effect of nerve growth factor on glutathione peroxidase and catalase in PC12 cells. Neurochemistry. 62:1994;2476-2479.
41. Sandstrom P.A., Mannie M.D., Buttke T.M. Inhibition of activation-induced death in T cell hybridomas by thiol antioxidants: oxidative stress as a mediator of apoptosis. J. Leukocyte Biol. 55:1994;221-226.
42. Slivka A., Cohen G. Hydroxyl radical attack on dopamine. J. biol. Chem. 260:1985;15466-15472.
43. Simantov R., Blinder H., Ratovitski T., Tauber M., Gabbay M., Porat S. Dopamine-induced apoptosis in human neuronal cells: Inhibition by nucleic acids antisense to the dopamine transporter. Neuroscience. 74:1996;39-50.
44. Sofic E., Lange K.W., Jellinger K., Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett. 142:1992;128-130.
45. Spina M.B., Squinto S.P., Miller J., Lindsay R.M., Hyman C. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system. J. Neurochem. 59:1992;99-106.
46. Tipton K.F., Singer T.P. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. Neurochemistry. 61:1993;1191-1206.
47. Walkinshaw G., Waters C.M. Neurotoxin-induced cell death in neuronal PC12 cells is mediated by induction of apoptosis. Neuroscience. 63:1994;975-987.
48. Winkler B.S., Orselli S.M., Rex T.S. The redox coupling between glutathione and ascorbic acid: a chemical and physiological perspective. Free Radic. Biol. Med. 17:1994;333-349.
49. Youdim M.B.H., Ben-Shachar D., Riederer P. The possible role of iron in the etiopathology of Parkinson's disease. Movement Disorders. 8:1993;1-12.
50. Zang L.Y., Misra H.P. Generation of reactive oxygen species during the monoamine oxidase-catalysed oxidation of the neurotoxicant, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. biol. Chem. 268:1993;16504-16512.
51. Zelnik N., Angel I., Paul S.M., Kleinman J.E. Decreased density of human striatal dopamine uptake sites with age. Europ. J. Pharmacol. 126:1986;175-176.
52. Zigmond M.J., Hastings T.G., Abercrombie E.D. Neurochemical responses to 6-hydroxydopamine and L-Dopa therapy: Implications for Parkinson's disease. Ann. N. Y. Acad. Sci. 648:1992;71-85.
53. Ziv I., Melamed E., Nardi N., Luria D., Achiron A., Offen D., Barzilai A. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons - a possible novel pathogenetic mechanism in Parkinson's disease. Neurosci. Lett. 170:1994;136-140.